Found 79 Chemotherapy trials
A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na ve Metastatic Anal Cancer Patients
This trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor …
Evaluating CART-EGFR-IL13Ra2 Cells Following Lymphodepleting Chemotherapy in Patients With EGFR-Amplified Recurrent Glioblastoma
This research study is being conducted to evaluate an experimental drug called CART EGFR-IL13Ra2 cells in patients with glioblastoma that has returned or worsened on current treatment.
keywords NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
TrialX NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Post market clinical follow up of Bycross® device.
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
UPCC 31218: A prospective multicentre randomised controlled study evaluating SIR-Spheres Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic CholangioCArcinoma (SIRCCA)
The main purpose of this research study is to find out whether Selective Internal Radiation Therapy (SIRT) preceding a standard chemotherapy treatment can improve survival in patients with cholangiocarcinoma in the liver, compared to chemotherapy alone.
Please choose between Voice or SMS based delivery of verification code
or